Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The aim of this study was to investigate the safety and efficacy of SHR-1210 in combination
with the anti-vascular survival target drug apatinib in patients with resectable NSCLC, and
to provide new treatment options for neoadjuvant therapy in patients with the period IB-IIIA
NSCLC.